About Us
Research & Development
Vascular Integrity
- Adrenomedullin
- Sepsis & Septic Shock
News & Events
Contact

About Us
Research & Development
Vascular Integrity
- Adrenomedullin
- Sepsis & Septic Shock
News & Events
Contact

JPM Healthcare Conference, 7-10 January, 2019

30. November 2018

JPM Healthcare Conference, 7-10 January, 2019, San Francisco, USA

Search for:

Adrenomed’s Adrecizumab successfully passes interim analysis in early septic shock study AdrenOSS-II

21. March 2019

Adrenomed AG participates in three upcoming conferences

12. March 2019

Adrenomed AG announces publication of Phase II trial design of Adrecizumab to treat septic shock

7. February 2019

International Opinion Leaders Align on Value of Adrenomedullin as Therapeutical Target and Biomarker in Sepsis and Acute Heart Failure

19. December 2018

Adrenomed closes € 24 M financing led by Wellington and HBM

26. November 2018

Adrenomed AG reveals Adrecizumab mode of action

14. June 2018

More News

Media Coverage

Article in MedNous: Adrenomed – a new approach for treating sepsis

21. January 2019

Article in ENDPOINTS: Wellington, HBM lead €24M round as Adrenomed preps septic shock treatment for human testing

27. November 2018

Article in SCRIP: Adrenomed Treads A New Path In Septic Shock

27. November 2018

Recent Events

12th Berlin Conference on Life Sciences, 14-15 March, 2019

8. March 2019

ISICEM, 39th International Symposium on Intensive Care and Emergency Medicine, March 19-22, 2019

7. March 2019

BIO-Europe Spring, 25-27 March, 2019

7. March 2019

ESC Heart Failure, 25-28 May, 2019

5. March 2019

JPM Healthcare Conference, 7-10 January, 2019

30. November 2018

More Events

CONTACT

Contact Info

+49 (0) 3302 20 77 8 0
+49 (0) 3302 20 77 8 15
info@adrenomed.com

ADRENOMED AG

Neuendorfstraße 15A
Hennigsdorf b. Berlin
D-16761, Germany.

Twitter Linkedin

Name

Subject

Message

I agree to the usage and processing of my personal data

JPM Healthcare Conference, 7-10 January, 2019

Recent News

Adrenomed’s Adrecizumab successfully passes interim analysis in early septic shock study AdrenOSS-II

Adrenomed AG participates in three upcoming conferences

Adrenomed AG announces publication of Phase II trial design of Adrecizumab to treat septic shock

International Opinion Leaders Align on Value of Adrenomedullin as Therapeutical Target and Biomarker in Sepsis and Acute Heart Failure

Adrenomed closes € 24 M financing led by Wellington and HBM

Adrenomed AG reveals Adrecizumab mode of action

Media Coverage

Article in MedNous: Adrenomed – a new approach for treating sepsis

Article in ENDPOINTS: Wellington, HBM lead €24M round as Adrenomed preps septic shock treatment for human testing

Article in SCRIP: Adrenomed Treads A New Path In Septic Shock

Recent Events

12th Berlin Conference on Life Sciences, 14-15 March, 2019

ISICEM, 39th International Symposium on Intensive Care and Emergency Medicine, March 19-22, 2019

BIO-Europe Spring, 25-27 March, 2019

ESC Heart Failure, 25-28 May, 2019

JPM Healthcare Conference, 7-10 January, 2019

Archive

CONTACT

Contact Info